NIHR Nottingham Digestive Diseases Centre Biomedical Research Unit, University of Nottingham, United Kingdom.
Int J Cardiol. 2013 Mar 20;164(1):77-81. doi: 10.1016/j.ijcard.2011.06.062. Epub 2011 Jul 23.
The liver is known to be structurally abnormal in long-standing Fontan circulation. The degree of liver dysfunction associated with such abnormalities is however largely unknown. We assessed structural changes (serum fibrosis markers) and function (indocyanine green clearance (ICG)) in Fontan patients.
21 stable Fontan patients were prospectively assessed and compared with 8 histologically proven compensated viral cirrhotic patients. All subjects had standard liver profile, "Enhanced Liver Fibrosis" (ELF) score (including hyaluronic acid, aminoterminal type III procollagen peptide P3NP and tissue inhibitor of metalloproteinase TIMP-1 levels), and ICG using the LiMON Device. Plasma disappearance rate (PDR) and 15-minute retention (R15) were recorded after ICG infusion.
Indocyanine clearance and retention (PDR and R15) were similar between Fontan and compensated cirrhotic patients (17 ± 5 vs 18 ± 6 (p=0.75) and 11 ± 10 vs 10 ± 10 (p=0.75)), as was degree of fibrosis (7.97 ± 1.16 vs 9.0 ± 1.43, p=NS). There was a positive correlation between PDR and ELF (R=0.77, p=0.028) as well as R15 and ELF (R=0.905, p=0.002) in the viral cirrhotics but not in the Fontan group. (R=-0.243, p=0.302; and R=0.226, p=0.338). PDR (17 ± 5) and R15 (11 ± 10) were not significantly different in Fontan as compared with the established cirrhotics.
Fontan patients have similar global hepatic function and fibrosis as compared with viral cirrhotic patients. However in Fontan patients, fibrosis was not closely correlated with global liver function, whereas viral cirrhotic patients exhibited a close correlation between function and fibrosis.
已知在长期的 Fontan 循环中肝脏存在结构异常。然而,与这种异常相关的肝功能障碍的程度在很大程度上尚不清楚。我们评估了 Fontan 患者的结构变化(血清纤维化标志物)和功能(吲哚菁绿清除率(ICG))。
前瞻性评估 21 例稳定的 Fontan 患者,并与 8 例经组织学证实的代偿性病毒性肝硬化患者进行比较。所有患者均进行了标准的肝功能检查、“增强型肝纤维化”(ELF)评分(包括透明质酸、氨基末端 III 型前胶原肽 P3NP 和金属蛋白酶组织抑制剂 TIMP-1 水平)以及使用 LiMON 设备进行 ICG。ICG 输注后记录血浆清除率(PDR)和 15 分钟保留率(R15)。
Fontan 组和代偿性肝硬化组的 ICG 清除率和保留率(PDR 和 R15)相似(17 ± 5 对 18 ± 6(p=0.75)和 11 ± 10 对 10 ± 10(p=0.75)),纤维化程度也相似(7.97 ± 1.16 对 9.0 ± 1.43,p=NS)。在病毒性肝硬化患者中,PDR 与 ELF 呈正相关(R=0.77,p=0.028),R15 与 ELF 也呈正相关(R=0.905,p=0.002),但在 Fontan 组中无相关性(R=-0.243,p=0.302;和 R=0.226,p=0.338)。与已建立的肝硬化患者相比,Fontan 患者的 PDR(17 ± 5)和 R15(11 ± 10)差异无统计学意义。
与病毒性肝硬化患者相比,Fontan 患者的整体肝功能和纤维化程度相似。然而,在 Fontan 患者中,纤维化与整体肝功能无密切相关性,而病毒性肝硬化患者的肝功能与纤维化之间存在密切相关性。